Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Twilio Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.45 (market cap $12.58B), while Twilio Inc trades at $290.79 (market cap $42.35B). The key difference: Twilio Inc is far larger — about 3.4× Halozyme Therapeutics Inc. Common Stock's market cap, and Halozyme Therapeutics Inc. Common Stock is more actively traded (2,179,278 versus 1,862,642). Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Twilio Inc for 56 Days on average.
| HALO | TWLO | |
|---|---|---|
Market Cap | $12.58B | $42.35B |
Volume | 2,179,278 | 1,862,642 |
Sector | Health | Technology |
52-Week High | $115.22 | $301.27 |
52-Week Low | $61.63 | $106.23 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $14.49B | $40.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Twilio (TWLO) trades at $289.18, up 5.93% in the past 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. The company's revenue growth accelerated to $5.07 billion in 2025, with net income turning positive at $33.83 million, and is projected to reach $1.1 billion in 2026. Recent inclusion in the S&P 500 index and positive analyst sentiment with 76.92% buy ratings highlight investor confidence, though high valuation multiples like a P/E of 38.09 and EV/EBITDA of 81.63 suggest premium pricing.
The outlook for Twilio is positive, driven by robust revenue growth, expanding profitability, and strategic positioning in AI-driven communications. Key risks include elevated valuation metrics that may limit upside, competitive pressures, and potential volatility from market reactions to earnings. Institutional interest remains strong, but investors should weigh growth prospects against current premium valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
